Abstract IA03: Engineering artificial antigen presenting cells, aAPC, for cancer immunotherapy: From bench to bedside

Adoptive Cellular Therapies, ACT, are promising immunotherapeutic approaches for treatment of cancer that, clinically, have had significant successes and yet many challenges remain that prevent ACT approaches from becoming front line therapy. In this presentation we will discuss the challenges associated with current approaches and show how artificial Antigen Presenting Cells, aAPC-based approaches help overcome those challenges. Thus, aAPC based approaches represent an off-shelf, scalable approach to production of clinical scale and grade T cells for the adoptive immunotherapy of cancer. Citation Format: Jonathan P. Schneck. Engineering artificial antigen presenting cells, aAPC, for cancer immunotherapy: From bench to bedside [abstract]. In: Abstracts: AACR Virtual Special Conference: Tumor Immunology and Immunotherapy; 2020 Oct 19-20. Philadelphia (PA): AACR; Cancer Immunol Res 2021;9(2 Suppl):Abstract nr IA03.